{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:31Z","timestamp":1792790491041,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12917-016-0851-0","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T10:35:36Z","timestamp":1475750136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-0018","authenticated-orcid":false,"given":"Alessandro","family":"Menozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Dall\u2019Aglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Quintavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Dallavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Meucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"851_CR1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3748\/wjg.v16.i9.1050","volume":"16","author":"M Cerquetella","year":"2010","unstructured":"Cerquetella M, Spaterna A, Laus F, Tesei B, Rossi G, Antonelli E, Villanacci V, Bassotti G. Inflammatory bowel disease in the dog: differences and similarities with humans. World J Gastroenterol. 2010;16:1050\u20136.","journal-title":"World J Gastroenterol"},{"key":"851_CR2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0140-6736(91)92104-A","volume":"338","author":"U Pirzer","year":"1991","unstructured":"Pirzer U, Schonhaar A, Fleischer B, Hermann E, Zumbuschenfelde KHM. Reactivity of infiltrating lymphocytes-T with microbial antigens in Crohns-disease. Lancet. 1991;338:1238\u20139.","journal-title":"Lancet"},{"key":"851_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0016-5085(98)70381-6","volume":"115","author":"C Fiocchi","year":"1998","unstructured":"Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182\u2013205.","journal-title":"Gastroenterology"},{"key":"851_CR4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(03)12489-0","volume":"361","author":"F Guarner","year":"2003","unstructured":"Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361:512\u20139.","journal-title":"Lancet"},{"key":"851_CR5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","volume":"109","author":"CO Elson","year":"1995","unstructured":"Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental-models of inflammatory bowel-disease. Gastroenterology. 1995;109:1344\u201367.","journal-title":"Gastroenterology"},{"key":"851_CR6","doi-asserted-by":"crossref","unstructured":"Neurath MF. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question (vol 22, pg 21, 2001). Trends Immunol. 2001;22:225\u201325","DOI":"10.1016\/S1471-4906(01)01891-9"},{"key":"851_CR7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2460\/ajvr.69.10.1279","volume":"69","author":"JR Dandrieux","year":"2008","unstructured":"Dandrieux JR, Bornand VF, Doherr MG, Kano R, Zurbriggen A, Burgener IA. Evaluation of lymphocyte apoptosis in dogs with inflammatory bowel disease. Am J Vet Res. 2008;69:1279\u201385.","journal-title":"Am J Vet Res"},{"key":"851_CR8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1939-1676.2007.tb03011.x","volume":"21","author":"K Allenspach","year":"2007","unstructured":"Allenspach K, Wieland B, Grone A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21:700\u20138.","journal-title":"J Vet Intern Med"},{"key":"851_CR9","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2460\/javma.1992.201.10.1603","volume":"201","author":"AE Jergens","year":"1992","unstructured":"Jergens AE, Moore FM, Haynes JS, Miles KG. Idiopathic inflammatory bowel disease in dogs and cats: 84 cases (1987\u20131990). J Am Vet Med Assoc. 1992;201:1603\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"851_CR10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1099\/00222615-35-4-238","volume":"35","author":"MH Giaffer","year":"1991","unstructured":"Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol. 1991;35:238\u201343.","journal-title":"J Med Microbiol"},{"key":"851_CR11","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","volume":"180","author":"JD Taurog","year":"1994","unstructured":"Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359\u201364.","journal-title":"J Exp Med"},{"key":"851_CR12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/0016-5085(84)90084-2","volume":"87","author":"MJ Blaser","year":"1984","unstructured":"Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn\u2019s disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology. 1984;87:888\u201394.","journal-title":"Gastroenterology"},{"key":"851_CR13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0016-5085(00)70362-3","volume":"118","author":"KL Madsen","year":"2000","unstructured":"Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology. 2000;118:1094\u2013105.","journal-title":"Gastroenterology"},{"key":"851_CR14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","volume":"106","author":"KJ Khan","year":"2011","unstructured":"Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661\u201373.","journal-title":"Am J Gastroenterol"},{"key":"851_CR15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000068362","volume":"66","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66:246\u201356.","journal-title":"Digestion"},{"key":"851_CR16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/gut.32.9.1071","volume":"32","author":"L Sutherland","year":"1991","unstructured":"Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al. Double-blind, placebo controlled trial of metronidazole in Crohns-disease. Gut. 1991;32:1071\u20135.","journal-title":"Gut"},{"key":"851_CR17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00054725-200201000-00002","volume":"8","author":"GL Arnold","year":"2002","unstructured":"Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8:10\u20135.","journal-title":"Inflamm Bowel Dis"},{"key":"851_CR18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0195-5616(99)50032-6","volume":"29","author":"AE Jergens","year":"1999","unstructured":"Jergens AE. Inflammatory bowel disease\u2013current perspectives. Veterinary Clinics of North America-Small Animal Practice. 1999;29:501\u201321.","journal-title":"Veterinary Clinics of North America-Small Animal Practice"},{"key":"851_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000238165","volume":"29","author":"AP Venturini","year":"1983","unstructured":"Venturini AP. Pharmacokinetics of L\/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy. 1983;29:1\u20133.","journal-title":"Chemotherapy"},{"key":"851_CR20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/17425250902973695","volume":"5","author":"V Ojetti","year":"2009","unstructured":"Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009;5:675\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"851_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","volume":"53","author":"J Yang","year":"2008","unstructured":"Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169\u201374.","journal-title":"Dig Dis Sci"},{"key":"851_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","volume":"142","author":"C Prantera","year":"2012","unstructured":"Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, Retic Study G. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease. Gastroenterology. 2012;142:473\u201381. e4.","journal-title":"Gastroenterology"},{"key":"851_CR23","first-page":"111","volume":"13","author":"EC Lauritano","year":"2009","unstructured":"Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, Fiore E, Flore R, Santoliquido A, Tondi P, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13:111\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"851_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","volume":"335","author":"J Cheng","year":"2010","unstructured":"Cheng J, Shah YM, Ma XC, Pang XY, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010;335:32\u201341.","journal-title":"J Pharmacol Exp Ther"},{"key":"851_CR25","first-page":"344","volume":"18","author":"L Ciobanu","year":"2014","unstructured":"Ciobanu L, Taulescu M, Prundus R, Diaconu B, Andreica V, Catoi C, Pascu O, Tantau M. Effects of rifaximin on indomethacin-induced intestinal damage in guinea-pigs. Eur Rev Med Pharmaco. 2014;18:344\u201351.","journal-title":"Eur Rev Med Pharmaco"},{"key":"851_CR26","doi-asserted-by":"crossref","unstructured":"Rossi G, Pengo G, Caldin M, Piccionello AP, Steiner JM, Cohen ND, Jergens AE, Suchodolski JS. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. Plos One. 2014;9:e94699.","DOI":"10.1371\/journal.pone.0094699"},{"key":"851_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1939-1676.2009.0447.x","volume":"24","author":"AE Jergens","year":"2010","unstructured":"Jergens AE, Crandell J, Morrison JA, Deitz K, Pressel M, Ackermann M, Suchodolski JS, Steiner JM, Evans R. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial. J Vet Intern Med. 2010;24:269\u201377.","journal-title":"J Vet Intern Med"},{"key":"851_CR28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1939-1676.2003.tb02450.x","volume":"17","author":"AE Jergens","year":"2003","unstructured":"Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med. 2003;17:291\u20137.","journal-title":"J Vet Intern Med"},{"key":"851_CR29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1939-1676.2003.tb01318.x","volume":"17","author":"AJ German","year":"2003","unstructured":"German AJ, Hall EJ, Day MJ. Chronic intestinal inflammation and intestinal disease in dogs. J Vet Intern Med. 2003;17:8\u201320.","journal-title":"J Vet Intern Med"},{"key":"851_CR30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1939-1676.2008.0093.x","volume":"22","author":"IA Burgener","year":"2008","unstructured":"Burgener IA, Konig A, Allenspach K, Sauter SN, Boisclair J, Doherr MG, Jungi TW. Upregulation of toll-like receptors in chronic enteropathies in dogs. J Vet Intern Med. 2008;22:553\u201360.","journal-title":"J Vet Intern Med"},{"key":"851_CR31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem CA, Loftus Jr EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707\u201312.","journal-title":"Inflamm Bowel Dis"},{"key":"851_CR32","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.3748\/wjg.v20.i44.16489","volume":"20","author":"JB Honneffer","year":"2014","unstructured":"Honneffer JB, Minamoto Y, Suchodolski JS. Microbiota alterations in acute and chronic gastrointestinal inflammation of cats and dogs. World J Gastroenterol. 2014;20:16489\u201397.","journal-title":"World J Gastroenterol"},{"key":"851_CR33","doi-asserted-by":"crossref","unstructured":"Cassmann E, White R, Atherly T, Wang C, Sun YX, Khoda S, Mosher C, Ackermann M, Jergens A. Alterations of the ileal and colonic mucosal microbiota in canine chronic enteropathies. Plos One. 2016;11","DOI":"10.1371\/journal.pone.0147321"},{"key":"851_CR34","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dkq345","volume":"65","author":"S Maccaferri","year":"2010","unstructured":"Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, Calanni F, Brigidi P, Gibson GR, Costabile A. Rifaximin modulates the colonic microbiota of patients with Crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65:2556\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"851_CR35","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/IAI.66.11.5224-5231.1998","volume":"66","author":"RK Sellon","year":"1998","unstructured":"Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224\u201331.","journal-title":"Infect Immun"},{"key":"851_CR36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4161\/gmic.22156","volume":"3","author":"G Loh","year":"2012","unstructured":"Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012;3:544\u201355.","journal-title":"Gut Microbes"},{"key":"851_CR37","doi-asserted-by":"crossref","first-page":"e51907","DOI":"10.1371\/journal.pone.0051907","volume":"7","author":"JS Suchodolski","year":"2012","unstructured":"Suchodolski JS, Markel ME, Garcia-Mazcorro JF, Unterer S, Heilmann RM, Dowd SE, Kachroo P, Ivanov I, Minamoto Y, Dillman EM, et al. The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. Plos One. 2012;7:e51907.","journal-title":"Plos One"},{"key":"851_CR38","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1748-5827.2004.tb00245.x","volume":"45","author":"M Craven","year":"2004","unstructured":"Craven M, Simpson JW, Ridyard AE, Chandler ML. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995\u20132002). J Small Anim Pract. 2004;45:336\u201342.","journal-title":"J Small Anim Pract"},{"key":"851_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1939-1676.2007.tb02922.x","volume":"21","author":"M Garcia-Sancho","year":"2007","unstructured":"Garcia-Sancho M, Rodriguez-Franco F, Sainz A, Mancho C, Rodriguez A. Evaluation of clinical, macroscopic, and histopathologic response to treatment in nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis. J Vet Intern Med. 2007;21:11\u20137.","journal-title":"J Vet Intern Med"},{"key":"851_CR40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/0016-5085(95)90121-3","volume":"108","author":"P Rutgeerts","year":"1995","unstructured":"Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn\u2019s recurrence after ileal resection. Gastroenterology. 1995;108:1617\u201321.","journal-title":"Gastroenterology"},{"key":"851_CR41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0016-5085(82)80189-3","volume":"83","author":"B Ursing","year":"1982","unstructured":"Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, et al. A comparative study of metronidazole and sulfasalazine for active Crohn\u2019s disease: the cooperative Crohn\u2019s disease study in Sweden. II. Result. Gastroenterology. 1982;83:550\u201362.","journal-title":"Gastroenterology"},{"key":"851_CR42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000231857","volume":"54","author":"DI Grove","year":"1977","unstructured":"Grove DI, Mahmound AA, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol. 1977;54:422\u20137.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"851_CR43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.intimp.2007.10.018","volume":"8","author":"M Fararjeh","year":"2008","unstructured":"Fararjeh M, Mohammad MK, Bustanji Y, Alkhatib H, Abdalla S. Evaluation of immunosuppression induced by metronidazole in Balb\/c mice and human peripheral blood lymphocytes. Int Immunopharmacol. 2008;8:341\u201350.","journal-title":"Int Immunopharmacol"},{"key":"851_CR44","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1185\/030079905X53252","volume":"21","author":"I Shafran","year":"2005","unstructured":"Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn\u2019s disease. Curr Med Res Opin. 2005;21:1165\u20139.","journal-title":"Curr Med Res Opin"},{"key":"851_CR45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","volume":"127","author":"T Langmann","year":"2004","unstructured":"Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26\u201340.","journal-title":"Gastroenterology"},{"key":"851_CR46","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mi.2014.31","volume":"7","author":"T Jakobsson","year":"2014","unstructured":"Jakobsson T, Vedin LL, Hassan T, Venteclef N, Greco D, D\u2019Amato M, Treuter E, Gustafsson JA, Steffensen KR. The oxysterol receptor LXRbeta protects against DSS- and TNBS-induced colitis in mice. Mucosal Immunol. 2014;7:1416\u201328.","journal-title":"Mucosal Immunol"},{"key":"851_CR47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejps.2014.01.007","volume":"55","author":"J Terc","year":"2014","unstructured":"Terc J, Hansen A, Alston L, Hirota SA. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci. 2014;55:12\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"851_CR48","doi-asserted-by":"crossref","first-page":"G1114","DOI":"10.1152\/ajpgi.00528.2006","volume":"292","author":"YM Shah","year":"2007","unstructured":"Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1114\u201322.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"851_CR49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.107.121913","volume":"322","author":"X Ma","year":"2007","unstructured":"Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007;322:391\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"851_CR50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.vetimm.2013.05.013","volume":"154","author":"H Okanishi","year":"2013","unstructured":"Okanishi H, Kabeya H, Maruyama S, Kagawa Y, Watari T. Activation of nuclear factor-kappa B and cell adhesion molecule mRNA expression in duodenal mucosa of dogs with lymphocytic-plasmacytic enteritis. Vet Immunol Immunop. 2013;154:145\u201352.","journal-title":"Vet Immunol Immunop"},{"key":"851_CR51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.vetimm.2009.08.014","volume":"133","author":"N Luckschander","year":"2010","unstructured":"Luckschander N, Hall JA, Gaschen F, Forster U, Wenzlow N, Hermann P, Allenspach K, Dobbelaere D, Burgener IA, Welle M. Activation of nuclear factor-kappaB in dogs with chronic enteropathies. Vet Immunol Immunopathol. 2010;133:228\u201336.","journal-title":"Vet Immunol Immunopathol"},{"key":"851_CR52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000084324","volume":"74","author":"A Menozzi","year":"2005","unstructured":"Menozzi A, Pozzoli C, Poli E, Lazzaretti M, Cantoni A, Grandi D, Giovannini E, Coruzzi G. Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat. Pharmacology. 2005;74:135\u201342.","journal-title":"Pharmacology"},{"key":"851_CR53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(01)01321-8","volume":"429","author":"O Culic","year":"2001","unstructured":"Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209\u201329.","journal-title":"Eur J Pharmacol"},{"key":"851_CR54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2460\/javma.1989.195.03.365","volume":"195","author":"SW Dow","year":"1989","unstructured":"Dow SW, LeCouteur RA, Poss ML, Beadleston D. Central nervous system toxicosis associated with metronidazole treatment of dogs: five cases (1984\u20131987). J Am Vet Med Assoc. 1989;195:365\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"851_CR55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002018-200023050-00006","volume":"23","author":"RB Stein","year":"2000","unstructured":"Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429\u201348.","journal-title":"Drug Saf"},{"key":"851_CR56","first-page":"263","volume":"5","author":"G Borelli","year":"1986","unstructured":"Borelli G, Bertoli D. Acute, subacute, chronic toxicity and mutagenicity studies of rifaximin (L\/105) in rats. Chemioterapia. 1986;5:263\u20137.","journal-title":"Chemioterapia"},{"key":"851_CR57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MPG.0b013e3181a0d269","volume":"49","author":"P Muniyappa","year":"2009","unstructured":"Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49:400\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 1","key":"851_CR58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","volume":"73","author":"C Scarpignato","year":"2006","unstructured":"Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13\u201327.","journal-title":"Digestion"},{"key":"851_CR59","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/vr.103557","volume":"178","author":"K Allenspach","year":"2016","unstructured":"Allenspach K, Culverwell C, Chan D. Long-term outcome in dogs with chronic enteropathies: 203 cases. The Veterinary record. 2016;178:368.","journal-title":"The Veterinary record"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-016-0851-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T01:46:09Z","timestamp":1749606369000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-016-0851-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1186\/s12917-016-0851-0","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]},"article-number":"217"}}